Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

NCT03535870 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

1556

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Fluticasone propionate/salmeterol
DRUG: Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder
DRUG: Placebo

Sponsor

West-Ward Pharmaceutical